Table 2.

Univariable (UVA) and multivariable (MVA) logistic regression model for prediction of treatment recommendation for clinical utility cohort

		UVA		MVA
Variable	Category	OR (95% CI)	P value	OR (95% CI)	P value
Age		1.0 (1.0–1.0)	0.563	1.0 (0.9–1.0)	0.006*
PSA		1.0 (1.0–1.0)	0.065	1.0 (1.0–1.0)	0.519
Pathological GG	3 vs 1–2	2.5 (2.0–3.3)	<0.001*	2.1 (1.4–2.9)	<0.001*
	4–5 vs 1–2	3.5 (2.7–4.5)	<0.001*	1.8 (1.2–2.6)	0.003*
Pathological T stage	pT3a vs pT2	1.4 (1.1–1.9)	0.013*	1.3 (0.8–2.0)	0.251
	pT3b vs pT2	2.8 (2.1–3.8)	<0.001*	1.7 (1.1–2.7)	0.030*
SM	Yes vs no	1.2 (1.0–1.5)	0.056	1.4 (1.0–2.0)	0.024*
GC risk group	Intermediate vs low	2.5 (1.7–3.8)	<0.001*	1.9 (1.1–3.3)	0.024*
	High vs low	9.5 (6.8–13.3)	<0.001*	8.5 (5.3–13.6)	<0.001*
CAPRA-S	3–5 vs 0–2	4.3 (1.5–12.1)	0.005*	3.9 (1.4–11.2)	0.011*
	6–12 vs 0–2	8.8 (3.2–24.6)	<0.001*	6.2 (2.1–17.6)	<0.001*
GC risk group	Intermediate vs low	2.5 (1.7–3.8)	<0.001*	1.9 (1.1–3.4)	0.019*
	High vs low	9.5 (6.8–13.3)	<0.001*	8.7 (5.4–13.8)	<0.001*

CAPRA-S Cancer of the Prostate Risk Assessment score, GC genomic classifiers, GG grade group, MVA multivariable analysis, OR odds ratio, PSA prostate-specific antigen, SM surgical margin, UVA univariable analysis, 95% CI 95% confidence interval, *significant p-value